1. Scrip
  2. >>Business

Cipla Signals US Launch Momentum, Commodity-Like Price Cycle

 
• By Anju Ghangurde

Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.

Pharma pills
CIPLA SIGNALS A RAMP-UP IN ITS US LAUNCH TRAJECTORY

Cipla Ltd.’s revenues slipped 3% to INR35.25bn ($549.5m) in the first quarter ended June impacted by disruption on account of implementation of India’s new Goods and Services Tax (GST) regime, but the firm's US business appears poised for a pick up backed by anticipated niche generic launches. Profit after tax rose 21% to INR4.09bn.

Cipla said it was on target to ramp-up its launch trajectory in the US and indicated that its base business out of the US was now averaging roughly $100m per...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.